eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

Genzyme Therapeutics
4620 Kingsgate, Cascade Way, Oxford Business Park South, Oxford, Oxfordshire, OX4 2SU
Telephone: +44 (0)1865 405 200
Fax: +44 (0)1865 774 172
WWW: http://www.genzyme.co.uk
Medical Information Direct Line: +44 (0)1865 405 200
Medical Information e-mail: ukmedinfo@genzyme.com
Customer Care direct line: +44 (0)1865 405 200
Medical Information Fax: +44 (0)1865 774 172

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 05/12/2011
PIL Fabrazyme 5 mg, powder for concentrate for solution for infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 05/12/2011 and displayed until Current
Reasons for adding or updating:
  • Change to, or new, use for medicine
Updated on 17/06/2011 and displayed until 05/12/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 10/02/2010 and displayed until 17/06/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 01/09/2008 and displayed until 10/02/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 16/06/2008 and displayed until 01/09/2008
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 11/04/2008 and displayed until 16/06/2008
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 26/11/2007 and displayed until 11/04/2008
Reasons for adding or updating:
  • Change to date of revision
Updated on 03/05/2007 and displayed until 26/11/2007
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Change to how to administer the medicine
  • Change to side-effects
Updated on 25/08/2006 and displayed until 03/05/2007
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

Active Ingredients/Generics

 
  agalsidase beta